These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 37715723)

  • 1. Phase 1 study of cabozantinib in combination with topotecan-cyclophosphamide for patients with relapsed Ewing sarcoma or osteosarcoma.
    Campbell K; Posner A; Chen N; Cavanaugh K; Bhushan K; Janeway KA; Shulman DS; George S; Klega K; Crompton B; London WB; DuBois SG
    Pediatr Blood Cancer; 2023 Dec; 70(12):e30681. PubMed ID: 37715723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase 1 study of simvastatin in combination with topotecan and cyclophosphamide in pediatric patients with relapsed and/or refractory solid and CNS tumors.
    Cash T; Jonus HC; Tsvetkova M; Beumer JH; Sadanand A; Lee JY; Henry CJ; Aguilera D; Harvey RD; Goldsmith KC
    Pediatr Blood Cancer; 2023 Aug; 70(8):e30405. PubMed ID: 37158620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial.
    Italiano A; Mir O; Mathoulin-Pelissier S; Penel N; Piperno-Neumann S; Bompas E; Chevreau C; Duffaud F; Entz-Werlé N; Saada E; Ray-Coquard I; Lervat C; Gaspar N; Marec-Berard P; Pacquement H; Wright J; Toulmonde M; Bessede A; Crombe A; Kind M; Bellera C; Blay JY
    Lancet Oncol; 2020 Mar; 21(3):446-455. PubMed ID: 32078813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study.
    Saylors RL; Stine KC; Sullivan J; Kepner JL; Wall DA; Bernstein ML; Harris MB; Hayashi R; Vietti TJ;
    J Clin Oncol; 2001 Aug; 19(15):3463-9. PubMed ID: 11481351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies.
    Paik PK; Rudin CM; Brown A; Rizvi NA; Takebe N; Travis W; James L; Ginsberg MS; Juergens R; Markus S; Tyson L; Subzwari S; Kris MG; Krug LM
    Cancer Chemother Pharmacol; 2010 Nov; 66(6):1079-85. PubMed ID: 20165849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I study of weekly doxorubicin and oral topotecan for patients with relapsed or refractory small cell lung cancer (SCLC): A Fred and Pamela Buffet Cancer Center Clinical Trials Network study.
    Ernani V; Jahan R; Smith LM; Marr AS; Kimbrough SE; Kos ME; Tijerina J; Pivovar S; Lakshmanan I; Ketcham M; Rauth S; Mallya K; Nasser MW; Jain M; Kessinger A; Batra SK; Ganti AK
    Cancer Treat Res Commun; 2020; 22():100162. PubMed ID: 31675535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclophosphamide and topotecan as first-line salvage therapy in patients with relapsed ewing sarcoma at a single institution.
    Farhat R; Raad R; Khoury NJ; Feghaly J; Eid T; Muwakkit S; Abboud M; El-Solh H; Saab R
    J Pediatr Hematol Oncol; 2013 Jul; 35(5):356-60. PubMed ID: 23042020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-Dose Metronomic Topotecan and Pazopanib (TOPAZ) in Children with Relapsed or Refractory Solid Tumors: A C17 Canadian Phase I Clinical Trial.
    Manji A; Samson Y; Deyell RJ; Johnston DL; Lewis VA; Zorzi AP; Berman JN; Brodeur-Robb K; Morrison E; Kee L; Kumar S; Baruchel S; Whitlock JA; Morgenstern DA
    Cancers (Basel); 2022 Jun; 14(12):. PubMed ID: 35740650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase-I dose escalation and sequencing study of docetaxel and continuous infusion topotecan in patients with advanced malignancies.
    Posey JA; Wang H; Hamilton J; Delgrosso A; Zhang R; Freda T; Zamboni WC
    Cancer Chemother Pharmacol; 2005 Aug; 56(2):182-8. PubMed ID: 15838660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pilot Study of Adding Vincristine, Topotecan, and Cyclophosphamide to Interval-Compressed Chemotherapy in Newly Diagnosed Patients With Localized Ewing Sarcoma: A Report From the Children's Oncology Group.
    Mascarenhas L; Felgenhauer JL; Bond MC; Villaluna D; Femino JD; Laack NN; Ranganathan S; Meyer J; Womer RB; Gorlick R; Krailo MD; Marina N
    Pediatr Blood Cancer; 2016 Mar; 63(3):493-8. PubMed ID: 26579879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study.
    Miller AA; Hargis JB; Lilenbaum RC; Fields SZ; Rosner GL; Schilsky RL
    J Clin Oncol; 1994 Dec; 12(12):2743-50. PubMed ID: 7527456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I clinical trial of weekly oral topotecan for relapsed small cell lung cancer.
    Agelaki S; Kontopodis E; Kotsakis A; Chandrinos V; Bompolaki I; Zafeiriou Z; Papadimitraki E; Stoltidis D; Kalbakis K; Georgoulias V
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):45-51. PubMed ID: 23604531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 1 study of oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic sarcoma.
    Choy E; Flamand Y; Balasubramanian S; Butrynski JE; Harmon DC; George S; Cote GM; Wagner AJ; Morgan JA; Sirisawad M; Mani C; Hornicek FJ; Duan Z; Demetri GD
    Cancer; 2015 Apr; 121(8):1223-30. PubMed ID: 25536954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A modified protocol with vincristine, topotecan, and cyclophosphamide for recurrent/progressive ewing sarcoma family tumors.
    Kebudi R; Cakir FB; Gorgun O; Agaoglu FY; Darendeliler E
    Pediatr Hematol Oncol; 2013 Apr; 30(3):170-7. PubMed ID: 23484903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intensive therapy with growth factor support for patients with Ewing tumor metastatic at diagnosis: Pediatric Oncology Group/Children's Cancer Group Phase II Study 9457--a report from the Children's Oncology Group.
    Bernstein ML; Devidas M; Lafreniere D; Souid AK; Meyers PA; Gebhardt M; Stine K; Nicholas R; Perlman EJ; Dubowy R; Wainer IW; Dickman PS; Link MP; Goorin A; Grier HE; ; ;
    J Clin Oncol; 2006 Jan; 24(1):152-9. PubMed ID: 16382125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.
    Younes A; Berdeja JG; Patel MR; Flinn I; Gerecitano JF; Neelapu SS; Kelly KR; Copeland AR; Akins A; Clancy MS; Gong L; Wang J; Ma A; Viner JL; Oki Y
    Lancet Oncol; 2016 May; 17(5):622-31. PubMed ID: 27049457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I and pharmacologic study of sequential topotecan-carboplatin-etoposide in patients with extensive stage small cell lung cancer.
    Miller AA; Al Omari A; Murry DJ; Case D
    Lung Cancer; 2006 Dec; 54(3):379-85. PubMed ID: 17049403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of topotecan in combination with cyclophosphamide in pediatric patients with malignant solid tumors: a Pediatric Oncology Group Study.
    Saylors RL; Stewart CF; Zamboni WC; Wall DA; Bell B; Stine KC; Vietti TJ
    J Clin Oncol; 1998 Mar; 16(3):945-52. PubMed ID: 9508177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 2 trial of palbociclib and ganitumab in patients with relapsed Ewing sarcoma.
    Shulman DS; Merriam P; Choy E; Guenther LM; Cavanaugh KL; Kao PC; Posner A; Bhushan K; Fairchild G; Barker E; Klega K; Stegmaier K; Crompton BD; London WB; DuBois SG
    Cancer Med; 2023 Jul; 12(14):15207-15216. PubMed ID: 37306107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bevacizumab, With Sorafenib and Cyclophosphamide Provides Clinical Benefit for Recurrent or Refractory Osseous Sarcomas in Children and Young Adults.
    Bodea J; Caldwell KJ; Federico SM
    Front Oncol; 2022; 12():864790. PubMed ID: 35692751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.